Adial Pharmaceuticals (NASDAQ:ADIL) versus Zelira Therapeutics (OTCMKTS:ZLDAF) Critical Analysis

Zelira Therapeutics (OTCMKTS:ZLDAF) and Adial Pharmaceuticals (NASDAQ:ADIL) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares Zelira Therapeutics and Adial Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zelira Therapeutics	N/A	N/A	N/A
Adial Pharmaceuticals	N/A	-191.31%	-153.59%

Earnings & Valuation

This table compares Zelira Therapeutics and Adial Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zelira Therapeutics	N/A	N/A	N/A	N/A	N/A
Adial Pharmaceuticals	N/A	N/A	-$13.20 million	($1.05)	-0.36

Insider and Institutional Ownership

16.4% of Adial Pharmaceuticals shares are owned by institutional investors. 4.3% of Adial Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Zelira Therapeutics and Adial Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zelira Therapeutics	0	0	0	0	0.00
Adial Pharmaceuticals	0	1	1	1	3.00

Adial Pharmaceuticals has a consensus price target of $8.00, suggesting a potential upside of 2,023.71%. Given Adial Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Adial Pharmaceuticals is more favorable than Zelira Therapeutics.

Summary

Adial Pharmaceuticals beats Zelira Therapeutics on 6 of the 8 factors compared between the two stocks.

About Zelira Therapeutics

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. The company offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. It also provides over the counter products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.